Verastem announced that the FDA has granted Orphan Drug designation to VS-5584 for the treatment of mesothelioma. VS-5584 is an orally available compound that has demonstrated potent and highly selective activity against class 1 PI3K enzymes and dual inhibitory actions against mTORC1 and mTORC2.
Currently a Phase 1 dose escalation trial for VS-5584 is ongoing in patients with advanced solid tumors as a single agent. Some patients have been in the advanced solid tumor study for over 6 months and the maximum tolerated dose of VS-5584 has not been reached. Verastem has also initiated a combination trial of VS-5584 and VS-6063 in patients with relapsed or progressive malignant pleural mesothelioma.
For more information visit Verastem.com.